natgillin/translations-raw huggingface dataset:
the sandwich immunoassay for PrPRes detection (short assay protocol) carried out following denaturation and concentration steps (Bio-Rad TeSeE SAP rapid test),
‚sendvič‘ imunološki preskus (sandwich immunoassay) za odkrivanje PrPRes, ki se izvede po denaturaciji in koncentraciji (test Bio-Rad Te-SeE);
the immunoassay using a chemical polymer for selective PrPSc capture and a monoclonal detection antibody directed against conserved regions of the PrP molecule (IDEXX HerdChek BSE Antigen Test Kit, EIA & IDEXX HerdChek BSE-Scrapie Antigen Test Kit, EIA),
imunološki preskus, ki temelji na selektivni vezavi PrPSc na kemijski polimer ter na detekcijskem monoklonskem protitelesu, usmerjenem proti ohranjenim delom molekule PrP (komplet IDEXX HerdChek BSE-Scrapie Antigen Test Kit, EIA, ter komplet IDEXX HerdChek BSE-Scrapie Antigen Test Kit, EIA),
For the purposes of carrying out the rapid tests in accordance with Articles 5(3) and 6(1), only the following methods shall be used as rapid tests for the monitoring of TSE in ovine and caprine animals:
Za izvajanje hitrih testov v skladu s členom 5(3) in členom 6(1) se kot hitri testi za spremljanje TSE pri ovcah in kozah uporabljajo le naslednje metode:
the immunoassay using a chemical polymer for selective PrPSc capture and a monoclonal detection antibody directed against conserved regions of the PrP molecule (IDEXX HerdChek BSE-Scrapie Antigen Test Kit, EIA).
imunološki preskus, ki temelji na selektivni vezavi PrPSc na kemijski polimer ter na detekcijskem monoklonskem protitelesu, usmerjenem proti ohranjenim delom molekule PrP (komplet IDEXX HerdChek BSE-Scrapie Antigen Test Kit, EIA),
In all rapid tests, sample tissue on which the test must be applied must comply with the manufacturer’s instructions for use.
Pri vseh hitrih testih mora vzorčno tkivo, ki se uporablja pri testu, ustrezati zahtevam iz proizvajalčevih navodil za uporabo.
Producers of rapid tests must have a quality assurance system in place that has been approved by the European Union Reference Laboratory and ensures that the test performance does not change.
Proizvajalci hitrih testov morajo imeti vzpostavljen sistem zagotavljanja kakovosti, ki ga je odobril referenčni laboratorij Evropske unije in ki zagotavlja, da se učinkovitost testiranja ne spreminja.
Producers must provide the European Union Reference Laboratory with the test protocols.
Proizvajalci morajo referenčnemu laboratoriju Evropske unije predložiti testne protokole.
Changes to rapid tests and to test protocols may only be made after prior notification to the European Union Reference Laboratory and provided that the European Union Reference Laboratory finds that the change does not alter the sensitivity, specificity or reliability of the rapid test.
Spremembe hitrih testov in testnih protokolov se lahko izvedejo le po predhodnem uradnem obvestilu, poslanem referenčnemu laboratoriju Evropske unije, in če referenčni laboratorij Evropske unije sklene, da sprememba ne zmanjša občutljivosti, specifičnosti ali zanesljivosti hitrega testa.
Commission Regulation (EU) No 957/2010
Uredba Komisije (EU) št. 957/2010
on the authorisation and refusal of authorisation of certain health claims made on foods and referring to the reduction of disease risk and to children’s development and health
o odobritvi in zavrnitvi odobritve nekaterih zdravstvenih trditev na živilih, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok
Two opinions referred to in this Regulation are related to applications for reduction of disease risk claims, as referred to in Article 14(1)(a) of Regulation (EC) No 1924/2006 and three opinions are related to applications for health claims referring to children’s development and health, as referred to in Article 14(1)(b) of Regulation (EC) No 1924/2006.
Dve mnenji iz te uredbe se nanašata na vlogi za zdravstveno trditev za zmanjšanje tveganja za nastanek bolezni, kakor je opredeljeno v členu 14(1)(a) Uredbe (ES) št. 1924/2006, tri mnenja pa se nanašajo na vloge za zdravstvene trditve v zvezi z razvojem in zdravjem otrok, kakor je opredeljeno v členu 14(1)(b) Uredbe (ES) št. 1924/2006.
Following an application from Association de la Transformation Laitière Française (ATLA), submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of iodine on normal growth of children (Question No EFSA-Q-2008-324) [2].
Družba Association de la Transformation Laitière Française (ATLA) je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi joda na normalno rast otrok (vprašanje št. EFSA-Q-2008-324) [2].
The claim proposed by the applicant was worded as follows: ‘Iodine is necessary for the growth of children’.
Vlagatelj je predlagal naslednjo trditev: „Jod je potreben za rast otrok.“
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 20 November 2009 that a cause and effect relationship had been established between the intake of iodine and the claimed effect.
Agencija je v svojem mnenju, ki so ga Komisija in države članice prejele 20. novembra 2009, na podlagi predloženih podatkov sklenila, da je bila vzročno-posledična povezava med uživanjem joda in navedeno trditvijo utemeljena.
Accordingly, a health claim reflecting this conclusion should be considered as complying with the requirements of Regulation (EC) No 1924/2006, and it should be included in the Union list of permitted claims.
Zdravstveno trditev, ki odraža ta sklep, je zato treba šteti za skladno z zahtevami iz Uredbe (ES) št. 1924/2006 ter jo uvrstiti na seznam dovoljenih trditev Unije.
Following an application from Association de la Transformation Laitière Française (ATLA), submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of iron on cognitive development of children (Question No EFSA-Q-2008-325) [3].
Družba Association de la Transformation Laitière Française (ATLA) je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi železa na kognitivni razvoj otrok (vprašanje št. EFSA-Q-2008-325) [3].
The claim proposed by the applicant was worded as follows: ‘Iron is necessary for the cognitive development of children’.
Vlagatelj je predlagal naslednjo trditev: „Železo je potrebno za kognitivni razvoj otrok“.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 20 November 2009 that a cause and effect relationship had been established between the intake of iron and the claimed effect.
Agencija je v svojem mnenju, ki so ga Komisija in države članice prejele 20. novembra 2009, na podlagi predloženih podatkov sklenila, da je bila vzročno-posledična povezava med uživanjem železa in navedeno trditvijo utemeljena.
Accordingly, those particulars should be set out in the Annex I to the present Regulation as regards the authorised claims and include, as the case may be, the revised wording of the claims, specific conditions of use of the claims, and, where applicable, conditions or restrictions of use of the food and/or an additional statement or warning, in accordance with the rules laid down in Regulation (EC) No 1924/2006 and in line with the opinions of the Authority.
Navedene podatke v zvezi z odobrenima trditvama je zato treba določiti v Prilogi I k tej uredbi ter vanje vključiti, odvisno od primera, spremenjeno besedilo trditev, posebne pogoje uporabe trditev in, kadar je to ustrezno, pogoje ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo v skladu s pravili iz Uredbe (ES) št. 1924/2006 in mnenji Agencije.
One of the objectives of Regulation (EC) No 1924/2006 is to ensure that health claims are truthful, clear and reliable and useful to the consumer, and that wording and presentation are taken into account in that respect.
Eden od ciljev Uredbe (ES) št. 1924/2006 je zagotoviti, da so zdravstvene trditve resnične, jasne, zanesljive in za potrošnika uporabne ter da se pri tem upoštevata besedilo in predstavitev trditve.
Therefore, where the wording of claims has the same meaning for consumers as that of an authorised health claim, because they demonstrate the same relationship that exists between a food category, a food or one of its constituents and health, they should be subject to the same conditions of use, as indicated in Annex I.
Kadar ima besedilo trditev za potrošnike enak pomen kot odobrena zdravstvena trditev, ker je med njima ista povezava kot med kategorijo živila, živilom ali njegovo sestavino in zdravjem, je treba te trditve uporabljati pod istimi pogoji, kot so navedeni v Prilogi I.
Following an application from GP International Holding BV, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of OPC PremiumTM on reduction of blood cholesterol (Question No EFSA-Q-2009-00454) [4].
Družba GP International Holding B.V. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki OPC PremiumTM na znižanje holesterola v krvi (vprašanje št. EFSA-Q-2009-00454) [4].
The claim proposed by the applicant was worded as follows: ‘OPC have been shown to reduce blood cholesterol levels and may therefore reduce the risk of cardiovascular disease’.
Vlagatelj je predlagal naslednjo trditev: „OPC dokazano znižuje raven holesterola v krvi in zato lahko zmanjša tveganje za bolezen srca in ožilja“.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 26 October 2009 that a cause and effect relationship had not been established between the intake of OPC PremiumTM and the claimed effect.
Agencija je v svojem mnenju, ki so ga Komisija in države članice prejele 26. oktobra 2009, na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem OPC PremiumTM ter navedeno trditvijo ni bila utemeljena.
Following an application from Valosun AS, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Uroval® on urinary tract infections (Question No EFSA-Q-2009-00600) [5].
Družba Valosun A.S. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Uroval® na okužbe urinarnega trakta (vprašanje št. EFSA-Q-2009-00600) [5].
The claim proposed by the applicant was worded as follows: ‘Cranberry extract and D-mannose, the main active ingredients of the food supplement Uroval®, eliminate the adhesion of harmful bacteria to the bladder wall.
Vlagatelj je predlagal naslednjo trditev: „Izvleček brusnic in D-manoza, glavni aktivni sestavini prehranskega dopolnila Uroval®, preprečujeta pritrjevanje škodljivih bakterij na steno sečnega mehurja.
The adhesion of harmful bacteria to the bladder wall is the main risk factor in the development of urinary tract infections’.
Pritrjevanje škodljivih bakterij na steno sečnega mehurja je glavno tveganje za nastanek okužb urinarnega trakta“.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 22 December 2009 that a cause and effect relationship had not been established between the intake of Uroval® and the claimed effect.
Agencija je v svojem mnenju, ki so ga Komisija in države članice prejele 22. decembra 2009, na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem Uroval® in navedeno trditvijo ni bila utemeljena.
Following an application from Töpfer GmbH, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of bifidobacteria (Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum) on decreasing potentially pathogenic intestinal micro-organisms (Question No EFSA-Q-2009-00224) [6].
Družba Töpfer GmbH je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije bifidobakterij (Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum) na zmanjšanje števila potencialno patogenih črevesnih mikroorganizmov (vprašanje št. EFSA-Q-2009-00224) [6].
The claim proposed by the applicant was worded as follows: ‘Probiotic bifidobacteria lead to a healthy intestinal flora comparable to the composition of the intestinal flora of breast-fed infants’ intestine’.
Vlagatelj je predlagal naslednjo trditev: „Probiotične bifidobakterije prispevajo k zdravi črevesni flori, ki je primerljiva s črevesno floro dojenčka, dojenega z materinim mlekom“.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 22 December 2009 that a cause and effect relationship had not been established between the intake of the combination of bifidobacteria and the claimed effect.
Agencija je v svojem mnenju, ki so ga Komisija in države članice prejele 22. decembra 2009, na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem kombinacije bifidobakterij in navedeno trditvijo ni bila utemeljena.
The health claims set out in Annex I to this Regulation may be made on foods on the European Union market in compliance with the conditions set out in that Annex.
Zdravstveni trditvi iz Priloge I k tej uredbi se lahko navedeta na živilih na trgu Evropske unije v skladu s pogoji iz navedene priloge.
Those health claims shall be included in the Union list of permitted claims referred to in Article 14(1) of Regulation (EC) No 1924/2006.
Navedeni zdravstveni trditvi se uvrstita na seznam dovoljenih trditev Unije iz člena 14(1) Uredbe (ES) št. 1924/2006.
The health claims set out in Annex II to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Zdravstvene trditve iz Priloge II k tej uredbi se ne uvrstijo na seznam dovoljenih trditev Unije v skladu s členom 14(1) Uredbe (ES) št. 1924/2006.
The EFSA Journal (2009) 7(11):1359.
The EFSA Journal (2009) 7(11), str. 1359.
The EFSA Journal (2009) 7(11):1360.
The EFSA Journal (2009) 7(11), str. 1360.
The EFSA Journal (2009) 7(10):1356.
The EFSA Journal (2009) 7(10), str. 1356.
The EFSA Journal (2009) 7(12):1421.
The EFSA Journal (2009) 7(12), str. 1421.
The EFSA Journal (2009) 7(12):1420.
The EFSA Journal (2009) 7(12), str. 1420.
Permitted health claims
Dovoljeni zdravstveni trditvi
Iodine contributes to the normal growth of children
Jod je potreben za rast otrok.
The claim can be used only for food which is at least a source of iodine as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006
Trditev se lahko navede le na živilu, ki je vsaj vir joda, kakor je opredeljeno s trditvijo VIR [IME VITAMINA/VITAMINOV] IN/ALI [IME MINERALA/MINERALOV] iz Priloge k Uredbi 1924/2006.
Iron contributes to normal cognitive development of children
Železo je potrebno za kognitivni razvoj otrok.
The claim can be used only for food which is at least a source of iron as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006
Trditev se lahko navede le na živilu, ki je vsaj vir železa, kakor je opredeljeno s trditvijo VIR [IME VITAMINA/VITAMINOV] IN/ALI [IME MINERALA/MINERALOV] iz Priloge k Uredbi 1924/2006.
OPC have been shown to reduce blood cholesterol levels and may therefore reduce the risk of cardiovascular disease
OPC dokazano znižuje raven holesterola v krvi in zato lahko zmanjša tveganje za bolezen srca in ožilja.
Cranberry extract and D-mannose, the main active ingredients of the food supplement Uroval®, eliminate the adhesion of harmful bacteria to the bladder wall.
Izvleček brusnic in D-manoza, glavni sestavini prehranskega dopolnila Uroval®, preprečujeta pritrjevanje škodljivih bakterij na steno sečnega mehurja.
The adhesion of harmful bacteria to the bladder wall is the main risk factor in the development of urinary tract infections
Pritrjevanje škodljivih bakterij na steno sečnega mehurja je glavno tveganje za nastanek okužb urinarnega trakta.
Combination of bifidobacteria (Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum)
kombinacija bifidobakterij (Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum)
Probiotic bifidobacteria lead to a healthy intestinal flora comparable to the composition of the intestinal flora of breast-fed infants’ intestine
Probiotične bifidobakterije prispevajo k zdravi črevesni flori, ki je primerljiva s črevesno floro dojenčka, dojenega z materinim mlekom.
Association de la Transformation Laitière Française (ATLA), 42 rue de Châteaudun, 75314 Paris Cedex 09, France
Association de la Transformation Laitière Française (ATLA), 42 rue de Châteaudun, 75314 Paris Cedex 09, Francija
Commission Regulation (EU) No 958/2010
Uredba Komisije (EU) št. 958/2010
The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’.
Nacionalni pristojni organ veljavne vloge posreduje Evropski agenciji za varnost hrane (v nadaljnjem besedilu: Agencija).
Following an application from Rudolf Wild GmbH & Co. KG, submitted on 10 June 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Immune Balance Drink on strengthening body’s defences (Question No EFSA-Q-2009-00517) [2].
Družba Rudolf Wild GmbH & Co. KG je 10. junija 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Immune Balance Drink na krepitev telesne odpornosti (vprašanje št. EFSA-Q-2009-00517) [2].
The claim proposed by the applicant was worded, inter alia, as follows: ‘The Immune Balance Drink activates body’s defence’.
Vlagatelj je med drugim predlagal naslednjo trditev: „The Immune Balance Drink aktivira telesno odpornost.“
On 4 November 2009, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Immune Balance Drink and the claimed effect.
Komisija in države članice so 4. novembra 2009 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Immune Balance Drink in navedeno trditvijo ni utemeljena.
The comments from the applicant and the members of the public received by the Commission, pursuant to Article 16(6) of Regulation (EC) No 1924/2006, have been considered when setting the measures provided for in this Regulation.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vlagatelj in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
As for the claim subject to the present Regulation, the Authority concluded that a cause and effect relationship had not been established between the consumption of the food and the claimed effect and thus it does not comply with the Regulation (EC) No 1924/2006 and it could not benefit from the transition period foreseen in Article 28(5) of that Regulation.
Ker je Agencija ugotovila, da v primeru trditve, ki je predmet te uredbe, vzročno-posledična povezava med uživanjem živila in navedeno trditvijo ni utemeljena ter zato ni v skladu z Uredbo (ES) št. 1924/2006, se prehodno obdobje iz člena 28(5) navedene uredbe ne more uporabiti.
The health claim set out in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
Zdravstvena trditev iz Priloge k tej uredbi se ne uvrsti na seznam dovoljenih trditev Unije v skladu s členom 13(3) Uredbe (ES) št. 1924/2006.
The EFSA Journal (2009) 7 (11):1357.
The EFSA Journal (2009) 7 (11), str. 1357.
The Immune Balance Drink activates body’s defence
Immune Balance Drink aktivira telesno odpornost.
Commission Regulation (EU) No 959/2010
Uredba Komisije (EU) št. 959/2010
This Regulation shall enter into force on 23 October 2010.
Ta uredba začne veljati 23. oktobra 2010.
Commission Regulation (EU) No 960/2010
Uredba Komisije (EU) št. 960/2010
This Regulation shall enter into force on 26 October 2010.
Ta uredba začne veljati 26. oktobra 2010.
Council Regulation (EU) No 961/2010
Uredba Sveta (EU) št. 961/2010
on restrictive measures against Iran and repealing Regulation (EC) No 423/2007
o omejevalnih ukrepih proti Iranu in razveljavitvi Uredbe (ES) št. 423/2007
Having regard to Council Decision 2010/413/CFSP of 26 July 2010 concerning restrictive measures against Iran and repealing Common Position 2007/140/CFSP [1],
ob upoštevanju Sklepa Sveta 2010/413/SZVP z dne 26. julija 2010 o omejitvenih ukrepih proti Iranu in razveljavitvi Skupnega stališča 2007/140/SZVP [1],
Having regard to the joint proposal from the High Representative of the Union for Foreign Affairs and Security Policy and the European Commission,
ob upoštevanju skupnega predloga visokega predstavnika Unije za zunanje zadeve in varnostno politiko ter Evropske komisije,
On 26 July 2010, the Council approved Decision 2010/413/CFSP confirming the restrictive measures taken since 2007 and providing for additional restrictive measures against the Islamic Republic of Iran (‘Iran’) in order to comply with UN Security Council Resolution 1929 (2010), as well as for accompanying measures as requested by the European Council in its Declaration of 17 June 2010.
Svet je 26. julija 2010 sprejel Sklep 2010/413/SZVP, ki je potrdil omejevalne ukrepe, ki so bili sprejeti v obdobju od leta 2007, in zagotovil dodatne omejevalne ukrepe proti Islamski republiki Iran (v nadaljnjem besedilu: Iran) v skladu z Resolucijo Varnostnega sveta ZN 1929 (2010) in spremljevalne ukrepe, kot je zahteval Evropski svet v svoji deklaraciji z dne 17. junija 2010.
Those restrictive measures comprise, in particular, additional restrictions on trade in dual-use goods and technology, as well as equipment which might be used for internal repression, restrictions on trade in key equipment and technology for, and restrictions on investment in the Iranian oil and gas industry, restrictions on Iranian investment in the uranium mining and nuclear industry, restrictions on transfers of funds to and from Iran, restrictions concerning the Iranian banking sector, restrictions on Iran's access to the insurance and bonds markets of the Union and restrictions on providing certain services to Iranian ships and cargo aircraft.
Navedeni omejevalni ukrepi so zlasti dodatne omejitve trgovine z blagom in tehnologijo z dvojno rabo ter z opremo, ki bi se lahko uporabila za notranjo represijo, omejitve trgovine s ključno opremo in tehnologijo za ter omejitve naložb v iransko naftno in plinsko industrijo, omejitve iranskih naložb v pridobivanje urana in jedrsko industrijo, omejitve prenosa sredstev v Iran in iz njega, omejitve v zvezi z iranskim bančnim sektorjem, omejitve dostopa Irana do zavarovalnih in delniških trgov Unije ter omejitve zagotavljanja določenih storitev za iranske ladje in tovorna letala.